The first evidence of an anticancer activity attributed to an NAPRT inhibitor was reported by our group in 2017 when we demonstrated that the prototypical NAPRT inhibitor 2-HNA cooperates with FK866 in blunting NAD+ levels in the NAPRT-proficient ovarian cancer OVCAR-5 cells. Here, NAPRT is linked to ovarian cancer.